Clinical Trials

80 enrolled

Colorectal Neoplasms

NCT05307198 2023-10-10

RAIC

38 enrolled

Rectal Neoplasms

NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

34 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

NCT04652440 2023-04-19

Ablation Combined With PD-1 in HCC: Phase II Study

Carcinoma, Hepatocellular

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

58 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04030260 2023-03-23

Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer

28 enrolled

Colorectal Cancer Metastatic

NCT05760196 2023-03-08

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

56 enrolled

Objective Response Rate

NCT05182957 2023-01-31

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Lymphoma, T-Cell, Peripheral

NCT05605613 2022-11-09

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

Phase 2/3 Unknown

150 enrolled

NSCLC

NCT05468138 2022-08-26

PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

141 enrolled

Stomach Neoplasms

NCT04459611 2022-07-12

neoSCORE

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03668431 2022-06-27

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

25 enrolled

Colorectal Neoplasms

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

120 enrolled

Breast

HER2+ Breast Cancer

NCT05201859 2022-05-06

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

150 enrolled

Nasopharyngeal Carcinoma

NCT04213404 2022-04-21

RISE-HN

Phase 1 Unknown

13 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04084626 2022-01-05

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

Phase 3 Unknown

Epstein-Barr Virus Infections

NCT05092217 2021-10-25

Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma

80 enrolled

Nasopharyngeal Carcinoma

NCT05039580 2021-09-09

SEHC

Phase 4 Unknown

36 enrolled

Epstein-Barr Virus Infections

NCT04943029 2021-09-02

NEOSUN

Carcinoma, Non-Small-Cell Lung

NCT04928365 2021-06-16

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

Dermatologic

Melanoma

NCT04909775 2021-06-02

Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder Carcinoma

NCT04790539 2021-03-10

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

71 enrolled

Extensive Stage Small Cell Lung Cancer

NCT03374293 2021-02-10

Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer

21 enrolled

Pancreatic Neoplasms

NCT04711434 2021-01-20

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Phase 3 Unknown

260 enrolled

Colorectal Neoplasms, Hereditary Nonpolyposis

NCT03989310 2020-12-23

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04676789 2020-12-21

SPENT

Lymphoma, Extranodal NK-T-Cell

NCT04663763 2020-12-11

Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

NCT04569916 2020-09-30

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Other solid neoplasm

Solid Tumor

NCT04411524 2020-06-02

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

NCT04411537 2020-06-02

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

NCT04385654 2020-05-13

Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma

Genitourinary

Kidney Neoplasms, Neoplasm Metastasis

NCT04279379 2020-05-07

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT04368273 2020-04-29

CCRT+PD-1

Gynecologic

Uterine Cervical Neoplasms

NCT04096690 2020-03-11

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

22 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT03991559 2019-08-28

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Phase 1 Unknown

Lymphoma, Neoplasm Metastasis

NCT04014101 2019-07-11

SHR-1210

Carcinoma, Hepatocellular

NCT04004234 2019-07-09

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT03914352 2019-04-16

A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection

Carcinoma, Hepatocellular, Recurrence

NCT03857815 2019-03-19

Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT03671265 2019-01-09

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Esophageal Neoplasms

NCT03722875 2018-12-19

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

45 enrolled

Carcinoma, Hepatocellular

NCT03619824 2018-10-09

PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

NCT03693326 2018-10-03

PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities